Lindsay C A, Bosso J A
Pharmacy Department, Texas Children's Hospital, Houston.
Clin Pharmacokinet. 1993 Jun;24(6):496-506. doi: 10.2165/00003088-199324060-00005.
Antibiotic therapy plays a central role in the medical management of patients with cystic fibrosis. While totally convincing efficacy data are lacking, antibiotics probably have a pronounced beneficial effect on both morbidity and mortality. Much has been learned in the past 20 years about antibiotic use in this population. At the same time, new antimicrobial agents with the potential to treat this condition have become available for use. The pharmacokinetics of a number of antibiotic classes, including beta-lactams, aminoglycosides and quinolones, are altered in this patient population. Increased total body clearance is a common occurrence but is not always changed enough to warrant altered dosages. Nonetheless, in light of altered pharmacokinetics in the cystic fibrosis population, appropriate dosage and monitoring parameters for a number of antibiotics have been determined.
抗生素治疗在囊性纤维化患者的医疗管理中起着核心作用。虽然缺乏完全令人信服的疗效数据，但抗生素可能对发病率和死亡率都有显著的有益影响。在过去20年里，人们对该人群使用抗生素有了很多了解。与此同时，有治疗这种疾病潜力的新型抗菌药物已可供使用。包括β-内酰胺类、氨基糖苷类和喹诺酮类在内的多种抗生素类别的药代动力学在该患者群体中发生了改变。全身清除率增加很常见，但变化幅度并不总是足以需要调整剂量。尽管如此，鉴于囊性纤维化人群药代动力学的改变，已确定了多种抗生素的适当剂量和监测参数。
